Millions Share a Deadly Genetic Heart Risk. This Experimental Drug Could Be a Game Changer
An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease. In clinical trial data published over the weekend, Eli Lilly’s lepodisiran was found to dramatically reduce people’s levels of a dangerous kind of cholesterol called lipoprotein (a), or Lp (a).
An experimental drug cuts genetic heart disease risk by 94% in trial: What we know
Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a mid-stage clinical trial involving 141 patients. Lp(a) is a genetic risk factor for heart attacks,
In a small Phase II trial, people with cocaine use disorder who took mavoglurant used the drug less often over a three month ...
A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.
A single dose of an experimental drug dramatically reduced levels of a deadly form of cholesterol, often thought to be ...
This is a major source of cardiovascular morbidity and mortality. We have never been able to treat lipoprotein(a) until now.” ...
For some people with a high risk of Alzheimer's who received a drug called gantenerumab for eight years, their risk of ...
Recursion Pharmaceuticals—a relatively small company backed by the chip giant Nvidia—is betting that its massive ...
The Eli Lilly drug caused a major drop in the blood levels of Lp(a), but further research is needed to show that it will ...
For the study, the researchers gave the study participants an experimental anti-amyloid drug. They found that 22 participants ...
In an exclusive interview with NBC News, President Donald Trump said there were methods that would allow him to seek a third ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback